Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.

about

Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations.Renal involvement in chronic lymphocytic leukemia

P2860

Q55515402-9DD1CF84-F523-4DED-9795-011E8EC24F1F Q57053852-CB874751-20AE-4D14-96E4-DE1522D91E45

P2860

Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.

Item

http://www.wikidata.org/entity/Q47887134

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.

@en

Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.

@nl

type

Item

label

Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.

@en

Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.

@nl

prefLabel

Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.

@en

Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.

@nl

P1476

Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents

@en

P2093

Bruce D Cheson

http://www.w3.org/2001/XMLSchema#string

Elisa Cerri

http://www.w3.org/2001/XMLSchema#string

Jalaja Potluri

http://www.w3.org/2001/XMLSchema#string

Monali Desai

http://www.w3.org/2001/XMLSchema#string

Nicole Lamanna

http://www.w3.org/2001/XMLSchema#string

Sari Heitner Enschede

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

The tumor lysis syndrome

Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies

Prevention and management of tumor lysis syndrome in adults with malignancy

Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

P304

1283-1291

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2017-0055

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Constantine S. Tam

P5008

ScienceSource

P577

2017-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28851760

http://www.w3.org/2001/XMLSchema#string

P921

chronic lymphocytic leukemia

peptide

proto-oncogene proteins

neoplasm proteins

lymphocyte

P932

5679833

http://www.w3.org/2001/XMLSchema#string

Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.

about

P2860

P2860

Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P50

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P50

P5008

P577

P698

P921

P932